Compare DNA & LXEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DNA | LXEO |
|---|---|---|
| Founded | 2008 | 2017 |
| Country | United States | United States |
| Employees | 485 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 418.0M | 486.1M |
| IPO Year | N/A | 2023 |
| Metric | DNA | LXEO |
|---|---|---|
| Price | $6.72 | $5.67 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 10 |
| Target Price | $8.50 | ★ $18.60 |
| AVG Volume (30 Days) | ★ 1.1M | 683.5K |
| Earning Date | 05-05-2026 | 03-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 75.08 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $654,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.00 | $1.45 |
| 52 Week High | $17.58 | $10.99 |
| Indicator | DNA | LXEO |
|---|---|---|
| Relative Strength Index (RSI) | 41.38 | 30.29 |
| Support Level | $6.46 | $4.67 |
| Resistance Level | $10.05 | $7.77 |
| Average True Range (ATR) | 0.44 | 0.51 |
| MACD | 0.05 | -0.11 |
| Stochastic Oscillator | 47.67 | 4.90 |
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering engaged in providing biological R&D services for customers across a range of industries and Biosecurity that provides services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.
Lexeo Therapeutics Inc is a clinical-stage genetic medicines company committed to transforming healthcare by applying pioneering science to fundamentally alter how diseases are treated. The company focuses on preclinical and clinical stage gene therapies, specifically hereditary and acquired diseases with high unmet needs, which represent its sole business segment.